Mild Cognitive Impairment – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Mild Cognitive Impairment – Pipeline Review, H2 2017’, provides an overview of the Mild Cognitive Impairment pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Mild Cognitive Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mild Cognitive Impairment and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Mild Cognitive Impairment

The report reviews pipeline therapeutics for Mild Cognitive Impairment by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Mild Cognitive Impairment therapeutics and enlists all their major and minor projects

The report assesses Mild Cognitive Impairment therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Mild Cognitive Impairment

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Mild Cognitive Impairment

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Mild Cognitive Impairment pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AgeneBio Inc

Avraham Pharmaceuticals Ltd

CereSpir Inc

ConSynance Therapeutics Inc

Eisai Co Ltd

Eli Lilly and Company

Ensol Biosciences Inc

Genzyme Corp

IntelGenx Corp

Krenitsky Pharmaceuticals Inc

Merck & Co Inc

Nanotherapeutics Inc

Neuron Biopharma SA

Pfizer Inc

Sage Therapeutics Inc

SBI Pharmaceuticals Co Ltd

Suven Life Sciences Ltd

Takeda Pharmaceutical Company Ltd

Therapix Biosciences Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Mild Cognitive Impairment - Overview

Mild Cognitive Impairment - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Mild Cognitive Impairment - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Mild Cognitive Impairment - Companies Involved in Therapeutics Development

AgeneBio Inc

Avraham Pharmaceuticals Ltd

CereSpir Inc

ConSynance Therapeutics Inc

Eisai Co Ltd

Eli Lilly and Company

Ensol Biosciences Inc

Genzyme Corp

IntelGenx Corp

Krenitsky Pharmaceuticals Inc

Merck & Co Inc

Nanotherapeutics Inc

Neuron Biopharma SA

Pfizer Inc

Sage Therapeutics Inc

SBI Pharmaceuticals Co Ltd

Suven Life Sciences Ltd

Takeda Pharmaceutical Company Ltd

Therapix Biosciences Ltd

Mild Cognitive Impairment - Drug Profiles

aminolevulinic acid hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BAN-2401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bosutinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

brexanolone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CSP-1103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CSTI-200 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DAOI-B - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dronabinol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

elenbecestat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KP-544 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ladostigil tartrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

levetiracetam ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

levofacetoperane - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3002813 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3303560 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

montelukast - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Moriah-1000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NPS-0158 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NPS-0163 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NST-0037 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NST-0076 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NST-0078 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NTC-942 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PAM-38 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Agonize Insulin Receptor for Mild Cognitive Impairment and Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sargramostim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize GABRA5 Receptor for CNS Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SUVN-501 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SUVN-507 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SUVN-512 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SUVNI-1307014 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SUVNI-1312004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-071 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tropisetron - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

verubecestat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Mild Cognitive Impairment - Dormant Projects

Mild Cognitive Impairment - Discontinued Products

Mild Cognitive Impairment - Product Development Milestones

Featured News & Press Releases

Aug 22, 2016: IntelGenx Announces Successful Clinical Study for Montelukast for the Treatment of Degenerative Diseases of the Brain

Jul 13, 2016: IntelGenx to Initiate Phase 1 Trial of Montelukast

Jul 28, 2015: Avraham Pharmaceuticals Announces Successful Second Interim Results in Phase 2b Study of Ladostigil for the Treatment of Mild Cognitive Impairment

Jul 14, 2015: CereSpir Obtains New Patent From USPTO Covering the Optimal Synthetic Route for Commercial Manufacture of CSP-1103 in Late Stage Development to Slow the Progression of Mild Cognitive Impairment Due to Alzheimer's Disease

Jul 01, 2015: CereSpir Submits Special Protocol Assessment Request to FDA for a Phase 3 Clinical Trial to Test the Ability of CSP-1103 to Slow the Progression of Mild Cognitive Impairment Due to Alzheimer's Disease

Jul 08, 2014: Avraham Pharmaceuticals Announces Successful Interim Results in Phase 2b Study of Ladostigil for the Treatment of MCI

Jul 26, 2013: CERESPIR INCORPORATED IS PLEASED WITH POSITIVE INTERIM PHASE 2 RESULTS FOR CHF 5074 IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT, PRESENTED BY CHIESI AT THE AAIC 2013 MEETING IN BOSTON

May 17, 2012: Avraham Initiates Phase II Ladostigil Study For Treatment Of Mild Cognitive Impairment

Apr 14, 2010: Alzheimer Drug Co Avraham Pharmaceuticals Raises $9m

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Mild Cognitive Impairment, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Mild Cognitive Impairment – Pipeline by AgeneBio Inc, H2 2017

Mild Cognitive Impairment – Pipeline by Avraham Pharmaceuticals Ltd, H2 2017

Mild Cognitive Impairment – Pipeline by CereSpir Inc, H2 2017

Mild Cognitive Impairment – Pipeline by ConSynance Therapeutics Inc, H2 2017

Mild Cognitive Impairment – Pipeline by Eisai Co Ltd, H2 2017

Mild Cognitive Impairment – Pipeline by Eli Lilly and Company, H2 2017

Mild Cognitive Impairment – Pipeline by Ensol Biosciences Inc, H2 2017

Mild Cognitive Impairment – Pipeline by Genzyme Corp, H2 2017

Mild Cognitive Impairment – Pipeline by IntelGenx Corp, H2 2017

Mild Cognitive Impairment – Pipeline by Krenitsky Pharmaceuticals Inc, H2 2017

Mild Cognitive Impairment – Pipeline by Merck & Co Inc, H2 2017

Mild Cognitive Impairment – Pipeline by Nanotherapeutics Inc, H2 2017

Mild Cognitive Impairment – Pipeline by Neuron Biopharma SA, H2 2017

Mild Cognitive Impairment – Pipeline by Pfizer Inc, H2 2017

Mild Cognitive Impairment – Pipeline by Sage Therapeutics Inc, H2 2017

Mild Cognitive Impairment – Pipeline by SBI Pharmaceuticals Co Ltd, H2 2017

Mild Cognitive Impairment – Pipeline by Suven Life Sciences Ltd, H2 2017

Mild Cognitive Impairment – Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017

Mild Cognitive Impairment – Pipeline by Therapix Biosciences Ltd, H2 2017

Mild Cognitive Impairment – Dormant Projects, H2 2017

Mild Cognitive Impairment – Dormant Projects, H2 2017 (Contd..1), H2 2017

Mild Cognitive Impairment – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Mild Cognitive Impairment, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports